Vertex Pharmaceuticals Incorporated (VRTX) EVP Amit Sachdev Sells 61 Shares

Share on StockTwits

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) EVP Amit Sachdev sold 61 shares of Vertex Pharmaceuticals stock in a transaction dated Wednesday, May 15th. The shares were sold at an average price of $165.41, for a total transaction of $10,090.01. Following the completion of the sale, the executive vice president now owns 33,416 shares in the company, valued at $5,527,340.56. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Vertex Pharmaceuticals stock traded down $1.50 during trading hours on Friday, hitting $168.73. 898,185 shares of the company traded hands, compared to its average volume of 1,399,861. The stock has a market cap of $43.68 billion, a price-to-earnings ratio of 59.62, a PEG ratio of 2.42 and a beta of 1.56. The company has a current ratio of 3.78, a quick ratio of 3.66 and a debt-to-equity ratio of 0.13. Vertex Pharmaceuticals Incorporated has a 1-year low of $144.07 and a 1-year high of $195.81.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Tuesday, April 30th. The pharmaceutical company reported $1.14 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.49. The firm had revenue of $857.00 million for the quarter, compared to analysts’ expectations of $853.00 million. Vertex Pharmaceuticals had a net margin of 66.01% and a return on equity of 22.63%. Vertex Pharmaceuticals’s quarterly revenue was up 34.3% on a year-over-year basis. During the same quarter last year, the company earned $0.76 EPS. Research analysts expect that Vertex Pharmaceuticals Incorporated will post 3.06 earnings per share for the current fiscal year.

Several analysts recently weighed in on the stock. BidaskClub downgraded shares of Vertex Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday. Zacks Investment Research downgraded shares of Vertex Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Friday, March 8th. Evercore ISI assumed coverage on shares of Vertex Pharmaceuticals in a research report on Thursday, April 11th. They issued an “in-line” rating and a $183.00 price objective on the stock. ValuEngine downgraded shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, April 18th. Finally, Cowen reiterated a “buy” rating and issued a $220.00 price objective on shares of Vertex Pharmaceuticals in a research report on Tuesday, April 30th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and fifteen have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $203.35.

A number of institutional investors have recently added to or reduced their stakes in VRTX. Neuberger Berman Group LLC increased its stake in Vertex Pharmaceuticals by 0.3% during the 3rd quarter. Neuberger Berman Group LLC now owns 249,092 shares of the pharmaceutical company’s stock valued at $48,010,000 after buying an additional 657 shares during the period. Morgan Stanley increased its stake in Vertex Pharmaceuticals by 11.1% during the 3rd quarter. Morgan Stanley now owns 690,767 shares of the pharmaceutical company’s stock valued at $133,137,000 after buying an additional 69,242 shares during the period. Vanguard Group Inc increased its stake in Vertex Pharmaceuticals by 1.2% during the 3rd quarter. Vanguard Group Inc now owns 18,775,252 shares of the pharmaceutical company’s stock valued at $3,618,743,000 after buying an additional 213,550 shares during the period. QUANTRES ASSET MANAGEMENT Ltd acquired a new position in shares of Vertex Pharmaceuticals in the 4th quarter worth approximately $431,000. Finally, First Citizens Bank & Trust Co. acquired a new position in shares of Vertex Pharmaceuticals in the 4th quarter worth approximately $807,000. 94.92% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “Vertex Pharmaceuticals Incorporated (VRTX) EVP Amit Sachdev Sells 61 Shares” was originally reported by Week Herald and is the sole property of of Week Herald. If you are accessing this article on another site, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The legal version of this article can be read at https://weekherald.com/2019/05/17/vertex-pharmaceuticals-incorporated-vrtx-evp-amit-sachdev-sells-61-shares.html.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene.

Further Reading: Is it Safe to Invest in Commodities?

Insider Buying and Selling by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.